Don’t panic after becoming resistant to Osimertinib

Resistance usually means that after a patient receives Osimertinib (Osimertinib) treatment for a period of time, the tumor’s efficacy against Osimertinib gradually weakens or completely fails. Osimertinib is a targeted drug for EGFR mutation-positive lung cancer. It is usually used to treat drug-resistant patients after treatment with first- or second-generation EGFR inhibitors. Understanding osimertinib resistance patterns, including targeted and non-targeted mechanisms, and their therapeutic potential is an unmet need in thoracic oncology.

Different resistance mechanisms develop when first-line and second-line drugs are administered. Standard treatments after progression to osimertinib include other targeted therapies (when targetable genetic alterations are detected) and cytotoxic chemotherapy (with or without anti-angiogenic and immunotherapeutic agents). After resistance to osimertinib, patients can choose to change drugs for treatment. For example, it can be replaced by Tagrisso (ametinib), which is a new generation of EGFR mutation-positive targeted drug that has a good inhibitory effect on the T790M mutation that appears after resistance to osimertinib.

OsimertinibThe original drug has been launched in China and has been covered by medical insurance. The price of 80mg*30 tablets per box may be around 5,000 yuan, which is relatively expensive. Currently available overseas Osimertinib generics, such as the specifications produced by Bangladesh Pharmaceutical FactoryThe price of each box of 80mg*30 tablets may be more than 800 yuan (the price may fluctuate due to exchange rate effects), which is relatively cheap. Osimertinib generics have basically the same pharmaceutical ingredients as the original drugs sold domestically and abroad. For more drug information and specific prices, please consult Yaode Medical Consultant.